M. Cappellini Et Al. , "A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia," BLOOD , vol.107, no.9, pp.3455-3462, 2006
Cappellini, M. Et Al. 2006. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. BLOOD , vol.107, no.9 , 3455-3462.
Cappellini, M., Cohen, A., Piga, A., Bejaoui, M., Perrone, S., Agaoglu, L., ... Aydinok, Y.(2006). A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. BLOOD , vol.107, no.9, 3455-3462.
Cappellini, MD Et Al. "A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia," BLOOD , vol.107, no.9, 3455-3462, 2006
Cappellini, MD Et Al. "A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia." BLOOD , vol.107, no.9, pp.3455-3462, 2006
Cappellini, M. Et Al. (2006) . "A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia." BLOOD , vol.107, no.9, pp.3455-3462.
@article{article, author={MD Cappellini Et Al. }, title={A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia}, journal={BLOOD}, year=2006, pages={3455-3462} }